Pacira BioSciences
PCRX
182 hedge funds and large institutions have $1.3B invested in Pacira BioSciences in 2016 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 60 increasing their positions, 59 reducing their positions, and 31 closing their positions.
107.68% more ownership
Funds ownership: 0% → 107.68% (+108%)
13% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 31
1% more funds holding
Funds holding: 180 → 182 (+2)
5% more call options, than puts
Call options by funds: $23.8M | Put options by funds: $22.6M
2% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 59
4% less capital invested
Capital invested by funds: $1.35B → $1.3B (-$47.4M)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$38.7M |
| 2 |
Millennium Management
New York
|
+$29.7M |
| 3 |
HM
HealthCor Management
New York
|
+$27.7M |
| 4 |
CCM
Consonance Capital Management
New York
|
+$21.1M |
| 5 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
+$18.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$85M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$41.1M |
| 3 |
NCGI
Next Century Growth Investors
Plymouth,
Minnesota
|
-$26.6M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$26.6M |
| 5 |
Goldman Sachs
New York
|
-$16.8M |
PCRX Hedge Fund Activity: Q4 2016 in Review
182 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q4 2016, worth a combined $1.3B — down 3.5% from $1.35B a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new PCRX positions and 31 closed out — a net gain of 4 holders — while 60 added to existing stakes and 59 trimmed.
The largest buyer was PFM Health Sciences, opening a new position worth an estimated $38.7M. The largest seller was Fidelity Investments, cutting an estimated $85M.
- 182 institutional investors held Pacira BioSciences (PCRX) as of Q4 2016, up from 180 in Q3 2016.
- Funds reported $1.3B of Pacira BioSciences stock for Q4 2016, down 3.5% quarter-over-quarter.
- 35 funds opened new Pacira BioSciences positions in Q4 2016 and 31 closed out, a net change of +4 holders.
- The largest Pacira BioSciences buyer in Q4 2016 was PFM Health Sciences, an estimated $38.7M added.
- The largest Pacira BioSciences seller in Q4 2016 was Fidelity Investments, an estimated $85M sold.
Based on aggregated 13F filings for Q4 2016.